Crystalvue is thrilled to announce that it has been awarded the prestigious Taiwan BIO Awards. Crystalvue's CEO, Dr. William Wang, had the privilege of meeting with President Tsai Ing-wen.
Crystalvue set a new monthly revenue record in June, with a monthly increase of 39% and an annual increase of 64% due to strong and steady sales in Europe and North America.
President Tsai meets the winners of 2021 Taiwan Bio Award. As the Gold Medal winner, Crystalvue General Manager, Mr. CP Chuang, was invited to meet President Tsai.
CV-700 is an Automated Patternless Workstation of Lens that combines tracing, edging, beveling, grooving, and blocking functions.
With steady increase in new orders and new product launch, Crystalvue is optimistic about the business outlook and targets double digit growth in 2022.
The winners of 2021 Taiwan BIO Awards Outstanding Award were announced, and Crystalvue won the Gold Award.
Crystalvue’s Automatic Non-Mydriatic Fundus Cameras, both NFC-700 and NFC-600, have been listed as one of the applicable devices for Acer VeriSee DR.
Crystalvue was awarded Gold Award by Taiwan Bio Industry Organization for the company's outstanding performance, growth strategies and technological innovation.
FDA has cleared Crystalvue Automated Portable Retinal Camera for sale in the United States.
With smart and patient-friendly feature design, Crystalvue NFC-700 was selected as Taiwan Excellence Product for 2020.
Crystalvue goes public through IPO on Taipei Exchange (6527-TW). The price went from $58.8 to $83.1 per share on the first day of IPO.
Industrial Technology Research Institute combines Crystalvue NFC-700 and diagnose software into a self-serving retinal camera, aiming to provide healthcare for remote areas.